Galectin Therapeutics Inc.

Galectin Therapeutics to Present at the American Association for the Study of Liver Diseases (AASLD) Liver Meeting 2026

Galectin Therapeutics will deliver three presentations, including an oral presentation and a Poster of Distinction, at the AASLD Liver Meeting 2026 in Denver on November 5-9. The presentations highlight new risk analyses on noninvasive prediction of variceal development from the NAVIGATE and GT-026 Phase 2b trials of belapectin in MASH cirrhosis with portal hypertension. The company also submitted the registrational Phase 3 protocol for belapectin to the FDA, an incremental advance toward a pivotal trial in an indication with no approved therapies.

•26d ago

Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update 

Galectin Therapeutics announced a major regulatory milestone, reaching an agreement with the FDA on the key elements of the planned Phase 3 trial for belapectin in MASH cirrhosis and portal hypertension, with a protocol submission expected in Q3 2026. The company significantly strengthened its balance sheet by converting approximately $105.8 million of debt and accrued interest from Chairman Richard E. Uihlein into 34.4 million shares of common stock, eliminating the liability. Q2 financial results show a net loss of $9.2 million, or $0.14 per share, with cash and equivalents of $13.2 million and an additional $10 million credit facility available to fund operations into June 2027.

•2mo ago

Galectin Therapeutics Announces Conversion of $105.8 Million in Debt to Equity, Significantly Strengthening Balance Sheet

Chairman Richard E. Uihlein converted approximately $105.8 million in debt across five credit facilities into 34,376,167 shares of common stock, effectively eliminating the company's outstanding principal and accrued interest under those agreements. The conversion strengthens the balance sheet significantly and increases total shares outstanding to 100,849,644, while a sixth facility providing up to $10 million remains undrawn and available. CEO Joel Lewis characterized the transaction as a transformative event that improves capitalization and underscores the Chairman's confidence in the company's galectin-3 inhibitor platform.

•2mo ago

Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension

Galectin Therapeutics announced a positive Type C meeting with the FDA, reaching agreement on the primary endpoint and regulatory path for a Phase 3 trial of belapectin in MASH cirrhosis with portal hypertension. The agency agreed to a composite liver outcome focused on preventing large esophageal varices, with the Company planning to evaluate a single 2 mg dose to support a full approval application. Galectin intends to submit the Phase 3 protocol in the third quarter of 2026 and is actively exploring strategic and financial partnerships to support the continued development and commercialization of the drug.

•4mo ago

Galectin Therapeutics Presents New EASL 2026 Oral and Poster Analyses Demonstrating Belapectin’s Potential to Modify Disease Progression in Advanced MASH Cirrhosis

Galectin Therapeutics presented new analyses from its NAVIGATE trial at EASL 2026, showing belapectin significantly reduces new varices development in high-risk MASH cirrhosis patients. The oral presentation demonstrated a mechanistic link between fibrogenesis modulation and reduced varices, while a designated TOP Poster showed significant reductions in clinically significant portal hypertension risk. Belapectin-treated patients had significantly less worsening of liver stiffness (11.7% vs 23.9% for placebo) and greater improvement in Baveno risk categories, reinforcing the drug's potential as a disease-modifying therapy.

•5mo ago

Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update

Galectin Therapeutics reported Q1 2026 results with a net loss of $5.1 million, significantly improved from $9.6 million in the prior year, driven by a drop in R&D spend to $2.2 million from $6.5 million. The company holds $14.1 million in cash plus $10 million in available credit, providing a runway through May 2027 without immediate need for dilutive financing. Positive biomarker data from the pivotal NAVIGATE trial showed statistically significant reductions in liver stiffness, supporting belapectin’s potential to impact disease progression in MASH cirrhosis patients. Upcoming catalysts include data presentations at the EASL congress in late May and a Type-C meeting with the FDA in Q2 2026 to align on next steps.

•5mo ago